A Phase 1 interventional study of Gepotidacin and Cimetidine in Infections, Bacterial, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-04.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing gepotidacin in Bacterial Infections — 1 open to participants now, 1 under way, none of them phase 3. gepotidacin · Bacterial Infections.
Among the 11 studies testing gepotidacin in Bacterial Infections, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 9 in phase 1, and was the 10th registered.
585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →1 of the 11 studies testing gepotidacin in Bacterial Infections is open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 2–11
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2020.
This study's enrollment of 64 is below the median of 84 across 383 interventional studies indexed under Bacterial Infections.
Median enrollment 34 across the 11 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Bacterial Infections by GlaxoSmithKline: 1 open now, 1 under way, none of them phase 3. Of 29 finished, 13 (45%) have results posted.
Among the 35 studies in Bacterial Infections by GlaxoSmithKline, this one is the 6th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2020, is one of 28 in phase 1, and was the 33rd registered.
GlaxoSmithKline’s Bacterial Infections studies by the year they started, since 2005.
1 of the studies testing gepotidacin in Bacterial Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371429GlaxoSmithKlineA Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics | 2027-08-23 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing gepotidacin in Bacterial Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Bacterial Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a drug-drug interaction (DDI), pharmacokinetics (PK), safety and tolerability study in adult healthy participants, including Japanese cohort. This study is designed to assess co-administration of probe substrates with gepotidacin in study cohorts 1 to 3 and establishing PK and safety in Japanese participants in cohort 4. Food effect will also be evaluated in cohort 4.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant has/had 2 Japanese parents and 4 Japanese grandparents who are/were all non-naturalized Japanese citizens, as confirmed by interview.
The participant has been living outside of Japan for up to 10 years as confirmed by interview.
Male and/or female: use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) before the first dose of study intervention and for women not on effective contraception at least 14 days prior to baseline visit.
The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
Exclusion Criteria:
Serum potassium >5.5 milliequivalent per liter (mEq/L) or \< 3.6 mEq/L Serum magnesium \<1.6 milligrams per deciliter (mg/dL) Serum calcium (total) \<8.5 mg/dL History of hypersensitivity to digoxin or other digitalis glycosides Any clinically relevant abnormality on 12-lead at Screening or Check-in.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a fixed sequence (Sequence AB) cohort. Participants will receive gepotidacin 1500 milligrams (mg) single dose (SD) on Day 1 of Period 1 (Treatment A); and Cimetidine 400 mg 4 times daily on Days 1 through 4 of Period 2 and gepotidacin 1500 mg single dose (Treatment B). Gepotidacin will be administered 1 hour after the first dose of cimetidine on Day 2 of Period 2. There will be a washout of at least 3 days between Treatment A and Treatment B, and a follow-up visit 5 to 7 days after the last dose of cimetidine.
Drug: Gepotidacin · Drug: Cimetidine
This is a fixed sequence (Sequence CDE) cohort. Participants will receive gepotidacin 1500 mg single dose on Day 1 of Period 1 (Treatment C), rifampicin 600 mg (administered in the evenings) once daily for 7 days (Days 1 through 7 of Period 2, to elicit maximal enzyme induction) (Treatment D); and gepotidacin 1500 mg single dose administered in the morning on Day 8 and rifampicin 600 mg administered in the evening on Days 8 and 9 of Period 2 (Treatment E). There will be a washout of at least 3 days between Treatment C and Treatment D, and a follow-up visit 7 to 10 days after the last dose of rifampicin.
Drug: Gepotidacin · Drug: Rifampicin
Participants will receive digoxin 0.5 mg and midazolam 2 mg (Treatment F) in Period 1 on Day 1 then gepotidacin two 3000 mg doses (given 12 hours apart) co-administered with digoxin 0.5 mg and midazolam 2 mg in Period 2 on Day 1, with the 2 probe drugs administered with the second daily dose of gepotidacin only (Treatment G). There will be a washout of at least 10 days between treatments. In Sequence 2, these regimens are reversed. A follow-up visit will occur 7 to 10 days after the last dose of study intervention in Period 2.
Drug: Gepotidacin · Drug: Midazolam · Drug: Digoxin
Participants will receive gepotidacin two 3000 mg doses (given 12 hours apart) co-administered with digoxin 0.5 mg and midazolam 2 mg in Period 1 on Day 1, with the 2 probe drugs administered with the second daily dose of gepotidacin only (Treatment G) followed by digoxin 0.5 mg and midazolam 2 mg (Treatment F) in Period 2 on Day 1. A follow-up visit will occur 7 to 10 days after the last dose of study intervention in Period 2.
Drug: Gepotidacin · Drug: Midazolam · Drug: Digoxin
Cohort 4 will include Japanese participants. Participants will receive a single dose of gepotidacin 1500 mg under fed conditions in Period 1 (Treatment H), then a single dose of gepotidacin 1500 mg under fasted conditions in Period 2 (Treatment I), followed by two doses of gepotidacin up to 3000 mg (given 12 hours apart) under fed conditions in Period 3 (Treatment J). There will be a washout of at least 3 days between each treatment, and a follow-up visit 5 to 7 days after the last dose of gepotidacin.
Drug: Gepotidacin
Cohort 4 will include Japanese participants. Participants will receive a single dose of gepotidacin 1500 mg under fasted conditions in Period 1 (Treatment I), then a single dose of gepotidacin 1500 mg under fed conditions in Period 2 (Treatment H), followed by two doses of gepotidacin up to 3000 mg (given 12 hours apart) under fed conditions in Period 3 (Treatment J). There will be a washout of at least 3 days between each treatment, and a follow-up visit 5 to 7 days after the last dose of gepotidacin.
Drug: Gepotidacin
Cohort 4 will include Japanese participants. Participants will receive a single dose of placebo under fed conditions in Period 1, then a single dose of placebo under fasted conditions in Period 2, followed by two doses of placebo (given 12 hours apart) under fed conditions in Period 3. There will be a washout of at least 3 days between each period, and a follow-up visit 5 to 7 days after the last dose of placebo.
Other: Placebo matching to gepotidacin
Gepotidacin tablets will be available as unit dose strength 750 mg and will be administered orally.
Also known as: GSK2140944
Cimetidine tablets will be available as unit dose strength 400 mg and will be administered orally.
Rifampicin Capsules will be available as unit dose strength 300 mg and will be administered orally.
Midazolam oral syrup 2 milligrams per milliliter (mg/mL) will be available to be administered orally.
Digoxin tablets will be available as unit dose strength 0.25 mg and will be administered orally.
Placebo matching to gepotidacin tablets will be administered orally.
Cohort 1: Maximum Observed Concentration (Cmax) of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric least square (LS) mean and 90 percent (%) confidence interval (CI) of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 1: Time to Reach Maximum Observed Concentration (Tmax) of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 1: Terminal Phase Half-life (t1/2) of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 1: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to the Time of the Last Quantifiable Concentration (AUC [0-t]) of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 1: AUC From Time 0 (Pre-dose) Extrapolated to Infinite Time (AUC[0-infinity]) of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 2: Cmax of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 2: Lag Time Before Observation of Drug Concentrations (Tlag) of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 2: Tmax of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 2: AUC(0-t) of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 2: AUC(0-infinity) of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 3: Cmax of Digoxin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 24 Hours, 36 Hours, 48 Hours, 72 Hours, 96 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 3: Tlag of Digoxin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 24 Hours, 36 Hours, 48 Hours, 72 Hours, 96 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 3: Tmax of Digoxin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 24 Hours, 36 Hours, 48 Hours, 72 Hours, 96 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 3: AUC(0-t) of Digoxin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 24 Hours, 36 Hours, 48 Hours, 72 Hours, 96 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 3: AUC(0-infinity) of Digoxin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 24 Hours, 36 Hours, 48 Hours, 72 Hours, 96 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 3: Cmax of Midazolam in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 3: Tlag of Midazolam in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 3: Tmax of Midazolam in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 3: AUC(0-t) of Midazolam in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 3: AUC(0-infinity) of Midazolam in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 4: Cmax of Gepotidacin Following Single Dose of 1500 mg in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: Tmax of Gepotidacin Following Single Dose of 1500 mg in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to the Concentration at 24 Hours Post-dose (AUC[0-24]) of Gepotidacin Following Single Dose of 1500 mg in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to the Concentration at 48 Hours Post-dose (AUC[0-48]) of Gepotidacin Following Single Dose of 1500 mg in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: AUC(0-t) of Gepotidacin Following Single Dose of 1500 mg in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: AUC(0-infinity) of Gepotidacin Following Single Dose of 1500 mg in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: Cmax of Gepotidacin in Plasma After the First Dose of 3000 mg -Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24, 36, 48, 60 Hours post-dose in Treatment Period 3
Cohort 4: Tmax of Gepotidacin in Plasma After the First Dose of 3000 mg -Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24, 36, 48, 60 Hours post-dose in Treatment Period 3
Cohort 4: AUC From Time 0 (Predose) to Time Tau (AUC[0-tau]) of Gepotidacin in Plasma After the First Dose of 3000 Mg-Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24, 36, 48, 60 Hours post-dose in Treatment Period 3
Cohort 4: Cmax of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose)-Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24, 36, 48, 60 Hours post-dose in Treatment Period 3
Cohort 4: Tmax of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose)-Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24, 36, 48, 60 Hours post-dose in Treatment Period 3
Cohort 4: AUC(0-tau) of Gepotidacin in Plasma After the Second Dose of 3000 mg (Evening Dose)-Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24, 36, 48, 60 Hours post-dose in Treatment Period 3
Cohort 4: Accumulation Ratio Based on Cmax (RoCmax) of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose)-Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Accumulation ratio was calculated as Cmax after the second dose divided by Cmax after the first dose.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24, 36, 48, 60 Hours post-dose in Treatment Period 3
Cohort 4: Accumulation Ratio Based on AUC(0-tau) (RoAUC) of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose)-Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Accumulation ratio was calculated as AUC(0-tau) after the second dose, where 0 is the timepoint prior to second dose, divided by AUC(0-tau) after the first dose, where 0 is the predose timepoint prior to the first dose.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24, 36, 48, 60 Hours post-dose in Treatment Period 3
Cohort 4: AUC(0-24) of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)-Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24 Hours post-dose in Treatment Period 3
Cohort 4: AUC(0-48) of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)-Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24, 36, 48 Hours post-dose in Treatment Period 3
Cohort 4: AUC(0-t) of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)-Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24, 36, 48, 60 Hours post-dose in Treatment Period 3
Cohort 4: Number of Participants With Serious Adverse Events (SAE) and Non-serious Adverse Events (Non-SAE)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situations as per Medical or scientific judgment.
Time frame: Up to 22 days
Cohort 4: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
Blood samples were collected at indicated time points for analysis of hematology parameters including Basophils, Eosinophils, Erythrocyte Mean Corpuscular Hemoglobin (MCH), Erythrocyte Mean Corpuscular Volume (MCV), Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose laboratory (lab) value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100 (%). High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 22 days
Cohort 4: Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
Blood samples were collected at indicated time points for analysis of clinical chemistry parameters including Alanine Aminotransferase (ALT), Albumin, Alkaline Phosphatase (Alk Phos), Aspartate Aminotransferase (AST), Bilirubin, Calcium, Carbon Dioxide, Chloride, Creatine Kinase, Creatinine, Direct Bilirubin, Glucose, Magnesium, Potassium, Protein, Sodium, Blood Urea Nitrogen (BUN). Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 22 days
Cohort 4: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Post-Baseline Relative to Baseline
Urine samples were collected at indicated time points for the analysis of urinalysis parameters including potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, nitrite, leukocyte esterase in urine by dipstick. Specific gravity of urine was measured by microscopic examination. Participants were counted in the worst case category that their value changes to (low, normal, high, or abnormal), unless there is no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 22 days
Cohort 4: Number of Participants With Worst Case Vital Sign Results Relative to Normal Range Post-Baseline Relative to Baseline
Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate were measured in a semi-supine position after 5 minutes rest. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 22 days
Cohort 4: Number of Participants With Any Increase in Maximum Post-Baseline Electrocardiogram (ECG) Parameter Corrected QT (QTc) Interval
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes using an ECG machine that automatically calculated the QTc interval. Number of participants with any increase of \>450 milliseconds in corrected QT interval using the Bazett formula (QTcB) Interval and corrected QT interval using the Fridericia formula (QTcF) Interval has been reported.
Time frame: Up to 22 days
Cohort 4: Cmax of Gepotidacin Following Single Dose of 1500 mg in Plasma - Food Effect in Japanese Participants
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: Tlag of Gepotidacin Following Single Dose of 1500 mg in Plasma - Food Effect in Japanese Participants
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: Tmax of Gepotidacin Following Single Dose of 1500 mg in Plasma - Food Effect in Japanese Participants
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: AUC(0-t) of Gepotidacin Following Single Dose of 1500 mg in Plasma - Food Effect in Japanese Participants
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: AUC(0-infinity) of Gepotidacin Following Single Dose of 1500 mg in Plasma - Food Effect in Japanese Participants
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 1: AUC (0-24) of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 1: AUC(0-48) of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 1: Tlag of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 1: Apparent Volume of Distribution (Vz/F) of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 1: Apparent Oral Clearance (CL/F) of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours Post-dose in each Treatment Periods 1 and 2
Cohort 1: Total Unchanged Drug (Ae Total) of Gepotidacin in Urine
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours Post-dose in each Treatment periods 1 and 2
Cohort 1: AUC(0-24) of Gepotidacin in Urine
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours Post-dose in each Treatment periods 1 and 2
Cohort 1: AUC(0-48) of Gepotidacin in Urine
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours Post-dose in each Treatment periods 1 and 2
Cohort 1: Renal Clearance (CLr) of Gepotidacin
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours Post-dose in each Treatment periods 1 and 2
Cohort 1: Amount of Drug Excreted in Urine in a Time Interval (Ae[t1-t2]) of Gepotidacin
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
Time frame: 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours post-dose in each Treatment periods 1 and 2
Cohort 1: Percentage of the Given Dose of Drug Excreted in Urine (fe%) of Gepotidacin
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. fe% was calculated as: (Ae total divided by Dose) multiplied by 100 percent (%).
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours Post-dose in each Treatment periods 1 and 2
Cohort 1: Number of Participants With SAE and Non-SAE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situations as per Medical or scientific judgment.
Time frame: Up to 17 days
Cohort 1: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
Blood samples were collected at indicated time points for analysis of hematology parameters including Basophils, Eosinophils, MCH, MCV, Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100 %. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 17 days
Cohort 1: Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
Blood samples were collected at indicated time points for analysis of clinical chemistry parameters including ALT, Albumin, Alk Phos, AST, Bilirubin, Calcium, Carbon Dioxide, Chloride, Creatine Kinase, Creatinine, Direct Bilirubin, Glucose, Magnesium, Potassium, Protein, Sodium, BUN. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 17 days
Cohort 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Post-Baseline Relative to Baseline
Urine samples were collected at indicated time points for the analysis of urinalysis parameters including pH of urine, presence of glucose, protein, blood, ketones, bilirubin, nitrite, leukocyte esterase in urine by dipstick. Specific gravity of urine was measured by microscopic examination. Participants were counted in the worst case category that their value changes to (low, normal, high, or abnormal), unless there is no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 17 days
Cohort 1: Number of Participants With Worst Case Vital Sign Results Relative to Normal Range Post-Baseline Relative to Baseline
Vital signs including SBP, DBP and pulse rate were measured in a semi-supine position after 5 minutes rest. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 17 days
Cohort 1: Number of Participants With Any Increase in Maximum Post-Baseline ECG Parameter QTc Interval
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes using an ECG machine that automatically calculated the QTc interval. Number of participants with any increase of \>450 milliseconds in corrected QT interval using the QTcB Interval and QTcF Interval has been reported.
Time frame: Up to 17 days
Cohort 2: AUC(0-24) of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours post-dose in each Treatment Periods 1 and 2
Cohort 2: AUC(0-48) of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 2: T1/2 of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 2: Vz/F of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 2: CL/F of Gepotidacin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 2: Ae Total of Gepotidacin in Urine
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 2: AUC(0-24) of Gepotidacin in Urine
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours post-dose in each Treatment Periods 1 and 2
Cohort 2: AUC(0-48) of Gepotidacin in Urine
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 2: CLr of Gepotidacin
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 2: Ae(t1-t2) of Gepotidacin
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
Time frame: 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 2: Percentage of the Given Dose of Drug Excreted in Urine (fe%) of Gepotidacin
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. fe% was calculated as: (Ae total divided by Dose) multiplied by 100 %.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 2: Number of Participants With SAE and Non-SAE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situations as per Medical or scientific judgment.
Time frame: Up to 26 days
Cohort 2: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
Blood samples were collected at indicated time points for analysis of hematology parameters including Basophils, Eosinophils, MCH, MCV, Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 26 days
Cohort 2: Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
Blood samples were collected at indicated time points for analysis of clinical chemistry parameters including ALT, Albumin, Alk Phos, AST, Bilirubin, Calcium, Carbon Dioxide, Chloride, Creatine Kinase, Creatinine, Direct Bilirubin, Glucose, Magnesium, Potassium, Protein, Sodium, BUN. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 26 days
Cohort 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Post-Baseline Relative to Baseline
Urine samples were collected at indicated time points for the analysis of urinalysis parameters including pH of urine, presence of glucose, protein, blood, ketones, bilirubin, nitrite, leukocyte esterase in urine by dipstick. Specific gravity of urine was measured by microscopic examination. Participants were counted in the worst case category that their value changes to (low, normal, high, or abnormal), unless there is no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 26 days
Cohort 2: Number of Participants With Worst Case Vital Sign Results Relative to Normal Range Post-Baseline Relative to Baseline
Vital signs including SBP, DBP and pulse rate were measured in a semi-supine position after 5 minutes rest. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 26 days
Cohort 2: Number of Participants With Any Increase in Maximum Post-Baseline ECG Parameter QTc Interval
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes using an ECG machine that automatically calculated the QTc interval. Number of participants with any increase of \>450 milliseconds in corrected QT interval using the QTcB Interval and QTcF Interval has been reported.
Time frame: Up to 26 days
Cohort 3: Cmax of Gepotidacin in Plasma After the First Dose of 3000 mg (First Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24,36, 48, 60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: Tmax of Gepotidacin in Plasma After the First Dose of 3000 mg (First Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24,36, 48, 60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: Tlag of Gepotidacin in Plasma After the First Dose of 3000 mg (First Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24,36, 48, 60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: AUC(0-tau) of Gepotidacin in Plasma First Dose of 3000 mg (First Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24,36, 48, 60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: Cmax of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24,36, 48, 60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: Tmax of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24,36, 48, 60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: AUC(0-tau) of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24,36, 48, 60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: RoCmax of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Accumulation ratio was calculated as Cmax after the second dose divided by Cmax after the first dose.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24,36, 48, 60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: RoAUC of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Accumulation ratio was calculated as AUC(0-tau) after the second dose, where 0 is the timepoint prior to second dose, divided by AUC(0-tau) after the first dose, where 0 is the predose timepoint prior to the first dose.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24,36, 48, 60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: AUC(0-24) of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: AUC(0-48) of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24,36, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: AUC(0-t) of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24,36, 48, 60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: Vz/F of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24,36, 48, 60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: CL/F of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24,36, 48, 60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: T1/2 of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose+ Second Dose)
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 Hours, 14 Hours, 14 Hours 30 Hours, 15, 16,18,20,24,36, 48, 60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: Minimum Observed Concentration (Cmin) of Digoxin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 24 Hours, 36 Hours, 48 Hours, 72 Hours, 96 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: T1/2 of Digoxin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 24 Hours, 36 Hours, 48 Hours, 72 Hours, 96 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: Vz/F of Digoxin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 24 Hours, 36 Hours, 48 Hours, 72 Hours, 96 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: CL/F of Digoxin in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 24 Hours, 36 Hours, 48 Hours, 72 Hours, 96 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: Cmin of Midazolam in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: T1/2 of Midazolam in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: Vz/F of Midazolam in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: CL/F of Midazolam in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: Ae Total of Gepotidacin in Urine Following Two 3000 mg Doses (First Dose + Second Dose )
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-14 Hours, 14-16 Hours, 16-18 Hours, 18-20 Hours, 20-24 Hours, 24-36 Hours, 36-48 Hours, 48-60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: Amount of Drug Excreted in Urine in a Time Interval (Ae[t1-t2]) of Gepotidacin Following Two 3000 mg Doses (First Dose + Second Dose)
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-14 Hours, 14-16 Hours, 16-18 Hours, 18-20 Hours, 20-24 Hours, 24-36 Hours, 36-48 Hours, 48-60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: AUC(0-tau) of Gepotidacin in Urine Following Two 3000 mg Doses (First Dose + Second Dose)
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-14 Hours, 14-16 Hours, 16-18 Hours, 18-20 Hours, 20-24 Hours, 24-36 Hours, 36-48 Hours, 48-60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: AUC(0-24) of Gepotidacin in Urine Following Two 3000 mg Doses (First Dose + Second Dose)
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-14 Hours, 14-16 Hours, 16-18 Hours, 18-20 Hours, 20-24 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: AUC (0-48) of Gepotidacin in Urine Following Two 3000 mg Doses (First Dose + Second Dose)
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-14 Hours, 14-16 Hours, 16-18 Hours, 18-20 Hours, 20-24 Hours, 24-36 Hours, 36-48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: Percentage of the Given Dose of Drug Excreted in Urine (fe%) Following Two 3000 mg Doses of Gepotidacin (First Dose + Second Dose )
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. fe% was calculated as: (Ae total divided by Dose) multiplied by 100 %.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-14 Hours, 14-16 Hours, 16-18 Hours, 18-20 Hours, 20-24 Hours, 24-36 Hours, 36-48 Hours, 48-60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: CLr of Gepotidacin Following Two 3000 mg Doses (First Dose + Second Dose)
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-14 Hours, 14-16 Hours, 16-18 Hours, 18-20 Hours, 20-24 Hours, 24-36 Hours, 36-48 Hours, 48-60 Hours post-dose in each Treatment Periods 1 and 2
Cohort 3: Number of Participants With SAE and Non-SAE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situations as per Medical or scientific judgment.
Time frame: Up to 30 days
Cohort 3: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
Blood samples were collected at indicated time points for analysis of hematology parameters including Basophils, Eosinophils, MCH, MCV, Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 30 days
Cohort 3: Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
Blood samples were collected at indicated time points for analysis of clinical chemistry parameters including ALT, Albumin, Alk Phos, AST, Bilirubin, Calcium, Carbon Dioxide, Chloride, Creatine Kinase, Creatinine, Direct Bilirubin, Glucose, Magnesium, Potassium, Protein, Sodium, BUN. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 30 days
Cohort 3: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Post-Baseline Relative to Baseline
Urine samples were collected at indicated time points for the analysis of urinalysis parameters including pH of urine, presence of glucose, protein, blood, ketones, bilirubin, nitrite, leukocyte esterase in urine by dipstick. Specific gravity of urine was measured by microscopic examination. Participants were counted in the worst case category that their value changes to (low, normal, high, or abnormal), unless there is no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 30 days
Cohort 3: Number of Participants With Worst Case Vital Sign Results Relative to Normal Range Post-Baseline Relative to Baseline
Vital signs including SBP, DBP and pulse rate were measured in a semi-supine position after 5 minutes rest. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 30 days
Cohort 3: Number of Participants With Any Increase in Maximum Post-Baseline ECG Parameter QTc Interval
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes using an ECG machine that automatically calculated the QTc interval. Number of participants with any increase of \>450 milliseconds in corrected QT interval using the QTcB Interval and QTcF Interval has been reported.
Time frame: Up to 30 days
Cohort 4: T1/2 of Gepotidacin Following Single Dose of 1500 mg in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: Vz/F of Gepotidacin Following Single Dose of 1500 mg in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: CL/F of Gepotidacin Following Single Dose of 1500 mg in Plasma
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hour, 2 Hours 30 minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours, 36 Hours, 48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: Tlag of Gepotidacin in Plasma After the First Dose of 3000 mg (First Dose)-Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24, 36, 48, 60 Hours post-dose in Treatment Period 3
Cohort 4: Vz/F of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)-Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24, 36, 48, 60 Hours post-dose in Treatment Period 3
Cohort 4: CL/F of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)-Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24, 36, 48, 60 Hours post-dose in Treatment Period 3
Cohort 4: T1/2 of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose )-Fed State
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 30 minutes, 1 Hour, 1 Hour 30 minutes, 2 Hours, 2 Hours 30 minutes, 3, 4, 6, 8, 12 Hours, 12 Hours 30 minutes, 13 Hours, 13 Hours 30 minutes, 14 Hours, 14 Hours 30 minutes, 15, 16, 18, 20, 24, 36, 48, 60 Hours post-dose in Treatment Period 3
Cohort 4: Ae Total of Gepotidacin Following Single Dose of 1500 mg Under Fed Condition in Urine
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: Ae(t1-t2) of Gepotidacin Following Single Dose of 1500 mg Under Fed Condition in Urine
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: AUC(0-24) of Gepotidacin Following Single Dose of 1500 mg Under Fed Condition in Urine
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: AUC(0-48) of Gepotidacin Following Single Dose of 1500 mg Under Fed Condition in Urine
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: Percentage of the Given Dose of Drug Excreted in Urine (fe%) for Gepotidacin 1500 mg Under Fed Condition
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. fe% was calculated as: (Ae total divided by Dose) multiplied by 100%.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: CLr of Gepotidacin Following Single Dose of 1500 mg Under Fed Condition
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours post-dose in each Treatment Periods 1 and 2
Cohort 4: Ae Total of Gepotidacin in Urine Following Two 3000 mg Doses-Fed State
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-14 Hours, 14-16 Hours, 16-18 Hours, 18-20 Hours, 20-24 Hours, 24-36 Hours, 36-48 Hours, 48-60 Hours post-dose in Treatment Period 3
Cohort 4: Ae(t1-t2) of Gepotidacin in Urine Following Two 3000 mg Doses-Fed State
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-14 Hours, 14-16 Hours, 16-18 Hours, 18-20 Hours, 20-24 Hours, 24-36 Hours, 36-48 Hours, 48-60 Hours post-dose in Treatment Period 3
Cohort 4: AUC(0-tau) of Gepotidacin in Urine Following Two 3000 mg Doses-Fed State
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-14 Hours, 14-16 Hours, 16-18 Hours, 18-20 Hours, 20-24 Hours, 24-36 Hours, 36-48 Hours, 48-60 Hours post-dose in Treatment Period 3
Cohort 4: AUC(0-24) of Gepotidacin in Urine Following Two 3000 mg Doses-Fed State
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-14 Hours, 14-16 Hours, 16-18 Hours, 18-20 Hours, 20-24 Hours post-dose in Treatment Period 3
Cohort 4: AUC(0-48) of Gepotidacin in Urine Following Two 3000 mg Doses-Fed State
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-14 Hours, 14-16 Hours, 16-18 Hours, 18-20 Hours, 20-24 Hours, 24-36 Hours, 36-48 Hours post-dose in Treatment Period 3
Cohort 4: Percentage of the Given Dose of Drug Excreted in Urine (fe%) of Gepotidacin Following Two 3000 mg Doses-Fed State
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. fe% was calculated as: (Ae total divided by Dose) multiplied by 100 %.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-14 Hours, 14-16 Hours, 16-18 Hours, 18-20 Hours, 20-24 Hours, 24-36 Hours, 36-48 Hours, 48-60 Hours post-dose in Treatment Period 3
Cohort 4: CLr of Gepotidacin Following Two 3000 mg Dose-Fed State
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-14 Hours, 14-16 Hours, 16-18 Hours, 18-20 Hours, 20-24 Hours, 24-36 Hours, 36-48 Hours, 48-60 Hours post-dose in Treatment Period 3
Cohort 4: AUC(0-tau) of Gepotidacin Following Single Dose of 1500 mg Under Fed Condition in Urine
Urine samples were collected at indicated time points. AUC(0-tau) can be calculated only for multiple doses and not for single dose as tau refers to the dosing interval. Hence, AUC(0-tau) could not be calculated for Gepotidacin 1500 mg single dose as mentioned in Reporting and Analysis Plan. The results for this outcome measure will never be posted.
Time frame: Pre-dose, 0-2 Hours, 2-4 Hours, 4-6 Hours, 6-8 Hours, 8-12 Hours, 12-24 Hours, 24-36 Hours, 36-48 Hours post-dose in each Treatment Periods 1 and 2
This study was conducted at a single center in the United States and designed to assess co-administration of probe substrates with gepotidacin in study Cohorts 1 to 3 and establishing pharmacokinetics and safety in a Japanese cohort in Cohort 4.
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 14 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 13 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 13 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 13 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 13 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 13 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 13 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 13 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 0 | 17 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 17 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 0 | 17 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 17 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 0 | 17 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 14 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 0 | 14 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 14 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 10 | 9 | 0 | 0 | 0 |
| Completed | 0 | 0 | 9 | 9 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 9 | 9 | 0 | 0 | 0 |
| Completed | 0 | 0 | 9 | 9 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 9 | 9 | 0 | 0 | 0 |
| Completed | 0 | 0 | 9 | 9 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 9 | 9 | 0 | 0 | 0 |
| Completed | 0 | 0 | 9 | 9 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 6 | 5 | 3 |
| Completed | 0 | 0 | 0 | 0 | 6 | 5 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 6 | 5 | 3 |
| Completed | 0 | 0 | 0 | 0 | 6 | 5 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 6 | 5 | 3 |
| Completed | 0 | 0 | 0 | 0 | 6 | 5 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 6 | 5 | 3 |
| Completed | 0 | 0 | 0 | 0 | 6 | 5 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 6 | 5 | 3 |
| Completed | 0 | 0 | 0 | 0 | 6 | 5 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 6 | 5 | 3 |
| Completed | 0 | 0 | 0 | 0 | 6 | 5 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric least square (LS) mean and 90 percent (%) confidence interval (CI) of the geometric LS means have been presented.
| Micrograms per milliliter | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: Maximum Observed Concentration (Cmax) of Gepotidacin in Plasma | 4.817 (4.006 to 5.793) | 4.548 (3.756 to 5.506) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: Time to Reach Maximum Observed Concentration (Tmax) of Gepotidacin in Plasma | 2.500 (1.00 to 4.00) | 2.500 (1.00 to 4.00) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
| Hours | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: Terminal Phase Half-life (t1/2) of Gepotidacin in Plasma | 11.344 (10.282 to 12.516) | 12.415 (11.207 to 13.754) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
| Hours*micrograms per milliliter | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to the Time of the Last Quantifiable Concentration (AUC [0-t]) of Gepotidacin in Plasma | 20.3 (17.7 to 23.3) | 23.4 (20.4 to 26.9) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
| Hours* micrograms per milliliter | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: AUC From Time 0 (Pre-dose) Extrapolated to Infinite Time (AUC[0-infinity]) of Gepotidacin in Plasma | 20.6 (18.0 to 23.6) | 23.9 (20.8 to 27.4) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
| Micrograms per milliliter | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: Cmax of Gepotidacin in Plasma | 3.735 (3.209 to 4.347) | 2.728 (2.323 to 3.202) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: Lag Time Before Observation of Drug Concentrations (Tlag) of Gepotidacin in Plasma | 0.000 (0 to 1.00) | 0.000 (0 to 0.50) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: Tmax of Gepotidacin in Plasma | 2.500 (1.00 to 6.00) | 2.000 (1.00 to 4.00) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
| Hours*micrograms per milliliter | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: AUC(0-t) of Gepotidacin in Plasma | 19.0 (16.9 to 21.3) | 9.0 (8.0 to 10.2) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Hours*micrograms per milliliter | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: AUC(0-infinity) of Gepotidacin in Plasma | 19.3 (17.2 to 21.7) | 9.3 (8.2 to 10.4) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Picograms per milliliter | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: Cmax of Digoxin in Plasma | 1553.135 (1318.390 to 1829.676) | 2381.259 (2013.503 to 2816.185) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis.
| Hours | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: Tlag of Digoxin in Plasma | 0.000 (0 to 0) | 0.000 (0 to 0) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis.
| Hours | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: Tmax of Digoxin in Plasma | 2.000 (0.50 to 4.00) | 1.275 (0.50 to 4.00) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Hours*picograms per milliliter | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: AUC(0-t) of Digoxin in Plasma | 25353.1 (22490.9 to 28579.6) | 30842.3 (27241.5 to 34919.0) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Hours*picograms per milliliter | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: AUC(0-infinity) of Digoxin in Plasma | 30743.6 (27425.5 to 34463.1) | 34456.5 (30652.1 to 38733.1) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Nanograms per milliliter | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: Cmax of Midazolam in Plasma | 5.238 (4.436 to 6.185) | 6.507 (5.492 to 7.711) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis.
| Hours | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: Tlag of Midazolam in Plasma | 0.000 (0 to 0) | 0.000 (0 to 0) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis.
| Hours | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: Tmax of Midazolam in Plasma | 0.650 (0.50 to 2.50) | 0.500 (0.50 to 4.00) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Hours*nanograms per milliliter | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: AUC(0-t) of Midazolam in Plasma | 23.3 (19.5 to 27.9) | 44.8 (37.4 to 53.8) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Hours*nanograms per milliliter | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: AUC(0-infinity) of Midazolam in Plasma | 24.9 (21.1 to 29.6) | 47.4 (39.9 to 56.4) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Micrograms per milliliter | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted |
|---|---|---|
| Cohort 4: Cmax of Gepotidacin Following Single Dose of 1500 mg in Plasma | 5.436 ± 27.8 | 5.143 ± 34.2 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted |
|---|---|---|
| Cohort 4: Tmax of Gepotidacin Following Single Dose of 1500 mg in Plasma | 2.000 (1.50 to 4.00) | 1.500 (1.00 to 4.00) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted |
|---|---|---|
| Cohort 4: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to the Concentration at 24 Hours Post-dose (AUC[0-24]) of Gepotidacin Following Single Dose of 1500 mg in Plasma | 20.9 ± 16.8 | 19.0 ± 12.9 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted |
|---|---|---|
| Cohort 4: Area Under the Concentration-time Curve From Time 0 (Pre-dose) to the Concentration at 48 Hours Post-dose (AUC[0-48]) of Gepotidacin Following Single Dose of 1500 mg in Plasma | 21.9 ± 16.0 | 20.0 ± 13.2 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted |
|---|---|---|
| Cohort 4: AUC(0-t) of Gepotidacin Following Single Dose of 1500 mg in Plasma | 21.9 ± 16.0 | 20.0 ± 13.2 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted |
|---|---|---|
| Cohort 4: AUC(0-infinity) of Gepotidacin Following Single Dose of 1500 mg in Plasma | 22.3 ± 15.5 | 20.4 ± 13.3 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Micrograms per milliliter | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: Cmax of Gepotidacin in Plasma After the First Dose of 3000 mg -Fed State | 11.204 ± 45.0 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: Tmax of Gepotidacin in Plasma After the First Dose of 3000 mg -Fed State | 2.000 (1.00 to 4.00) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: AUC From Time 0 (Predose) to Time Tau (AUC[0-tau]) of Gepotidacin in Plasma After the First Dose of 3000 Mg-Fed State | 37.3 ± 25.4 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Micrograms per milliliter | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: Cmax of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose)-Fed State | 12.363 ± 21.3 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: Tmax of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose)-Fed State | 2.000 (1.00 to 3.00) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: AUC(0-tau) of Gepotidacin in Plasma After the Second Dose of 3000 mg (Evening Dose)-Fed State | 46.7 ± 23.1 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Accumulation ratio was calculated as Cmax after the second dose divided by Cmax after the first dose.
| Ratio | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: Accumulation Ratio Based on Cmax (RoCmax) of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose)-Fed State | 1.103 ± 39.3 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Accumulation ratio was calculated as AUC(0-tau) after the second dose, where 0 is the timepoint prior to second dose, divided by AUC(0-tau) after the first dose, where 0 is the predose timepoint prior to the first dose.
| Ratio | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: Accumulation Ratio Based on AUC(0-tau) (RoAUC) of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose)-Fed State | 1.254 ± 13.1 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: AUC(0-24) of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)-Fed State | 84.6 ± 23.1 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: AUC(0-48) of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)-Fed State | 90.8 ± 22.9 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: AUC(0-t) of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)-Fed State | 91.4 ± 23.0 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situations as per Medical or scientific judgment.
| Participants | Cohort 4: Placebo | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|---|---|---|
| Any SAE | 0 | 0 | 0 | 0 |
| Any non-SAE | 0 | 1 | 2 | 4 |
Blood samples were collected at indicated time points for analysis of hematology parameters including Basophils, Eosinophils, Erythrocyte Mean Corpuscular Hemoglobin (MCH), Erythrocyte Mean Corpuscular Volume (MCV), Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose laboratory (lab) value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100 (%). High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 4: Placebo | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|---|---|---|
| Basophils; To Low | 0 | 0 | 0 | 0 |
| Basophils; To Normal or No Change | 3 | 11 | 9 | 10 |
| Basophils; To High | 0 | 0 | 2 | 1 |
| Eosinophils; To Low | 0 | 0 | 0 | 0 |
| Eosinophils; To Normal or No Change | 3 | 10 | 10 | 10 |
| Eosinophils; To High | 0 | 1 | 1 | 1 |
| MCH; To Low | 0 | 0 | 0 | 0 |
| MCH; To Normal or No Change | 3 | 11 | 11 | 11 |
| MCH; To High | 0 | 0 | 0 | 0 |
| MCV; To Low | 0 | 0 | 0 | 0 |
| MCV; To Normal or No Change | 2 | 10 | 10 | 9 |
| MCV; To High | 1 | 1 | 1 | 2 |
| Erythrocytes; To Low | 0 | 0 | 0 | 1 |
| Erythrocytes; To Normal or No Change | 3 | 10 | 11 | 10 |
| Erythrocytes; To High | 0 | 1 | 0 | 0 |
| Hematocrit; To Low | 0 | 0 | 0 | 0 |
| Hematocrit; To Normal or No Change | 3 | 10 | 11 | 10 |
| Hematocrit; To High | 0 | 1 | 0 | 1 |
| Hemoglobin; To Low | 0 | 0 | 0 | 0 |
| Hemoglobin; To Normal or No Change | 3 | 10 | 11 | 11 |
| Hemoglobin; To High | 0 | 1 | 0 | 0 |
| Leukocytes; To Low | 0 | 0 | 0 | 1 |
| Leukocytes; To Normal or No Change | 3 | 11 | 11 | 10 |
| Leukocytes; To High | 0 | 0 | 0 | 0 |
| Lymphocytes; To Low | 0 | 0 | 0 | 0 |
| Lymphocytes; To Normal or No Change | 3 | 11 | 11 | 11 |
| Lymphocytes; To High | 0 | 0 | 0 | 0 |
| Monocytes; To Low | 0 | 0 | 0 | 0 |
| Monocytes; To Normal or No Change | 3 | 11 | 11 | 11 |
| Monocytes; To High | 0 | 0 | 0 | 0 |
| Neutrophils; To Low | 0 | 0 | 1 | 1 |
| Neutrophils; To Normal or No Change | 3 | 11 | 10 | 10 |
| Neutrophils; To High | 0 | 0 | 0 | 0 |
| Platelets; To Low | 0 | 0 | 0 | 1 |
| Platelets; To Normal or No Change | 3 | 11 | 11 | 10 |
| Platelets; To High | 0 | 0 | 0 | 0 |
Blood samples were collected at indicated time points for analysis of clinical chemistry parameters including Alanine Aminotransferase (ALT), Albumin, Alkaline Phosphatase (Alk Phos), Aspartate Aminotransferase (AST), Bilirubin, Calcium, Carbon Dioxide, Chloride, Creatine Kinase, Creatinine, Direct Bilirubin, Glucose, Magnesium, Potassium, Protein, Sodium, Blood Urea Nitrogen (BUN). Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 4: Placebo | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|---|---|---|
| ALT; To Low | 0 | 0 | 0 | 0 |
| ALT; To Normal or No Change | 3 | 11 | 11 | 11 |
| ALT; To High | 0 | 0 | 0 | 0 |
| Albumin; To Low | 1 | 0 | 0 | 0 |
| Albumin; To Normal or No Change | 2 | 11 | 11 | 11 |
| Albumin; To High | 0 | 0 | 0 | 0 |
| Alk Phos; To Low | 0 | 0 | 0 | 0 |
| Alk Phos; To Normal or No Change | 3 | 11 | 11 | 11 |
| Alk Phos; To High | 0 | 0 | 0 | 0 |
| AST; To Low | 0 | 0 | 0 | 0 |
| AST; To Normal or No Change | 3 | 11 | 11 | 11 |
| AST; To High | 0 | 0 | 0 | 0 |
| Bilirubin; To Low | 0 | 0 | 0 | 0 |
| Bilirubin; To Normal or No Change | 2 | 11 | 11 | 11 |
| Bilirubin; To High | 1 | 0 | 0 | 0 |
| Calcium; To Low | 0 | 0 | 0 | 0 |
| Calcium; To Normal or No Change | 3 | 11 | 11 | 11 |
| Calcium; To High | 0 | 0 | 0 | 0 |
| Carbon Dioxide; To Low | 0 | 0 | 1 | 0 |
| Carbon Dioxide; To Normal or No Change | 3 | 11 | 10 | 11 |
| Carbon Dioxide; To High | 0 | 0 | 0 | 0 |
| Chloride; To Low | 0 | 0 | 0 | 0 |
| Chloride; To Normal or No Change | 3 | 11 | 11 | 11 |
| Chloride; To High | 0 | 0 | 0 | 0 |
| Creatine Kinase; To Low | 1 | 0 | 0 | 1 |
| Creatine Kinase; To Normal or No Change | 2 | 11 | 11 | 9 |
| Creatine Kinase; To High | 0 | 0 | 0 | 1 |
| Creatinine; To Low | 0 | 0 | 0 | 0 |
| Creatinine; To Normal or No Change | 3 | 11 | 11 | 11 |
| Creatinine;To High | 0 | 0 | 0 | 0 |
| Direct Bilirubin; To Low | 0 | 0 | 0 | 0 |
| Direct Bilirubin; To Normal or No Change | 2 | 11 | 11 | 11 |
| Direct Bilirubin; To High | 1 | 0 | 0 | 0 |
| Glucose; To Low | 0 | 0 | 0 | 0 |
| Glucose; To Normal or No Change | 3 | 11 | 11 | 11 |
| Glucose; To High | 0 | 0 | 0 | 0 |
| Magnesium; To Low | 0 | 0 | 0 | 0 |
| Magnesium; To Normal or No Change | 3 | 11 | 11 | 11 |
| Magnesium; To High | 0 | 0 | 0 | 0 |
| Potassium; To Low | 0 | 0 | 0 | 0 |
| Potassium; To Normal or No Change | 2 | 11 | 11 | 11 |
| Potassium; To High | 1 | 0 | 0 | 0 |
| Protein; To Low | 0 | 0 | 0 | 0 |
| Protein; To Normal or No Change | 3 | 11 | 11 | 11 |
| Protein; To High | 0 | 0 | 0 | 0 |
| Sodium; To Low | 0 | 0 | 0 | 0 |
| Sodium; To Normal or No Change | 3 | 11 | 11 | 11 |
| Sodium; To High | 0 | 0 | 0 | 0 |
| BUN; To Low | 0 | 0 | 0 | 0 |
| BUN; To Normal or No Change | 3 | 11 | 11 | 11 |
| BUN; To High | 0 | 0 | 0 | 0 |
Urine samples were collected at indicated time points for the analysis of urinalysis parameters including potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, nitrite, leukocyte esterase in urine by dipstick. Specific gravity of urine was measured by microscopic examination. Participants were counted in the worst case category that their value changes to (low, normal, high, or abnormal), unless there is no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 4: Placebo | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|---|---|---|
| Bilirubin; To Normal or No Change | 3 | 11 | 11 | 11 |
| Bilirubin; To Abnormal | 0 | 0 | 0 | 0 |
| Glucose; To Normal or No Change | 3 | 11 | 11 | 11 |
| Glucose; To Abnormal | 0 | 0 | 0 | 0 |
| Ketones; To Normal or No Change | 2 | 11 | 11 | 11 |
| Ketones; To Abnormal | 1 | 0 | 0 | 0 |
| Leukocyte Esterase; To Normal or No Change | 2 | 9 | 11 | 9 |
| Leukocyte Esterase; To Abnormal | 1 | 2 | 0 | 2 |
| Nitrite; To Normal or No Change | 3 | 11 | 11 | 10 |
| Nitrite; To Abnormal | 0 | 0 | 0 | 1 |
| Occult Blood; To Normal or No Change | 2 | 11 | 10 | 10 |
| Occult Blood; To Abnormal | 1 | 0 | 1 | 1 |
| Protein; To Normal or No Change | 3 | 11 | 11 | 11 |
| Protein; To Abnormal | 0 | 0 | 0 | 0 |
| pH; To Low | 0 | 0 | 0 | 0 |
| pH; To Normal or No Change | 3 | 11 | 11 | 11 |
| pH; To High | 0 | 0 | 0 | 0 |
| Specific Gravity; To Low | 0 | 0 | 0 | 0 |
| Specific Gravity; To Normal or No Change | 3 | 11 | 11 | 11 |
| Specific Gravity; To High | 0 | 0 | 0 | 0 |
Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate were measured in a semi-supine position after 5 minutes rest. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 4: Placebo | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|---|---|---|
| DBP; To Low | 0 | 1 | 0 | 0 |
| DBP; To Normal or No Change | 3 | 10 | 11 | 11 |
| DBP; To High | 0 | 0 | 0 | 0 |
| SBP; To Low | 0 | 1 | 1 | 0 |
| SBP; To Normal or No Change | 3 | 10 | 10 | 11 |
| SBP; To High | 0 | 0 | 0 | 0 |
| Pulse rate; To Low | 0 | 0 | 0 | 0 |
| Pulse rate; To Normal or No Change | 3 | 11 | 11 | 11 |
| Pulse rate; To High | 0 | 0 | 0 | 0 |
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes using an ECG machine that automatically calculated the QTc interval. Number of participants with any increase of \>450 milliseconds in corrected QT interval using the Bazett formula (QTcB) Interval and corrected QT interval using the Fridericia formula (QTcF) Interval has been reported.
| Participants | Cohort 4: Placebo | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|---|---|---|
| QTcB Interval | 1 | 8 | 3 | 9 |
| QTcF Interval | 1 | 1 | 0 | 2 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Micrograms per milliliter | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted |
|---|---|---|
| Cohort 4: Cmax of Gepotidacin Following Single Dose of 1500 mg in Plasma - Food Effect in Japanese Participants | 5.421 (4.610 to 6.374) | 5.158 (4.386 to 6.065) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted |
|---|---|---|
| Cohort 4: Tlag of Gepotidacin Following Single Dose of 1500 mg in Plasma - Food Effect in Japanese Participants | 0.000 (0 to 0.50) | 0.000 (0 to 0) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted |
|---|---|---|
| Cohort 4: Tmax of Gepotidacin Following Single Dose of 1500 mg in Plasma - Food Effect in Japanese Participants | 2.000 (1.50 to 4.00) | 1.500 (1.00 to 4.00) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Hours*Micrograms per milliliter | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted |
|---|---|---|
| Cohort 4: AUC(0-t) of Gepotidacin Following Single Dose of 1500 mg in Plasma - Food Effect in Japanese Participants | 21.9 (20.3 to 23.7) | 20.0 (18.5 to 21.6) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Hours*Micrograms per milliliter | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted |
|---|---|---|
| Cohort 4: AUC(0-infinity) of Gepotidacin Following Single Dose of 1500 mg in Plasma - Food Effect in Japanese Participants | 22.3 (20.7 to 24.1) | 20.4 (18.9 to 22.0) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: AUC (0-24) of Gepotidacin in Plasma | 19.3 ± 32.6 | 21.9 ± 29.7 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: AUC(0-48) of Gepotidacin in Plasma | 20.3 ± 31.4 | 23.0 ± 28.4 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: Tlag of Gepotidacin in Plasma | 0.000 (0 to 0.50) | 0.000 (0 to 0) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Liters | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: Apparent Volume of Distribution (Vz/F) of Gepotidacin in Plasma | 1190.16 ± 34.0 | 1143.29 ± 30.6 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Liters per Hour | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: Apparent Oral Clearance (CL/F) of Gepotidacin in Plasma | 72.72 ± 31.2 | 64.14 ± 28.0 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Milligrams | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: Total Unchanged Drug (Ae Total) of Gepotidacin in Urine | 337.92 (281.14 to 406.16) | 410.10 (343.16 to 490.08) |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
| Hours*micrograms per milliliter | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: AUC(0-24) of Gepotidacin in Urine | 3292.1 (2639.2 to 4106.5) | 3612.4 (2888.5 to 4517.7) |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
| Hours*micrograms per milliliter | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: AUC(0-48) of Gepotidacin in Urine | 3578.2 (2890.1 to 4430.0) | 3831.1 (3087.7 to 4753.4) |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90% CI of the geometric LS means have been presented.
| Liters per Hour | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: Renal Clearance (CLr) of Gepotidacin | 16.06 (14.18 to 18.18) | 17.59 (15.62 to 19.81) |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
| Milligrams | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Ae (0-2), n=14, 13 | 28.66 ± 185.9 | NA ± NA |
| Ae (2-4), n=14, 12 | 89.18 ± 120.8 | 142.99 ± 42.7 |
| Ae (4-6), n=14, 13 | 50.52 ± 119.1 | 82.77 ± 44.0 |
| Ae (6-8); n=14, 13 | 34.38 ± 56.2 | 46.22 ± 55.3 |
| Ae (8-12), n=12, 13 | 29.90 ± 38.3 | 30.97 ± 38.0 |
| Ae (12-24), n=14, 13 | 25.44 ± 38.1 | 22.04 ± 121.3 |
| Ae (24-36), n=14, 13 | 10.88 ± 43.1 | 8.76 ± 89.6 |
| Ae (36-48), n=14, 13 | 4.50 ± 39.3 | 4.08 ± 88.5 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. fe% was calculated as: (Ae total divided by Dose) multiplied by 100 percent (%).
| Percent dose excreted | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Cohort 1: Percentage of the Given Dose of Drug Excreted in Urine (fe%) of Gepotidacin | 22.72 ± 53.2 | 26.90 ± 21.3 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situations as per Medical or scientific judgment.
| Participants | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Any SAE | 0 | 0 |
| Any non-SAE | 0 | 0 |
Blood samples were collected at indicated time points for analysis of hematology parameters including Basophils, Eosinophils, MCH, MCV, Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100 %. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Basophils; To Low | 0 | 0 |
| Basophils; To Normal or No Change | 14 | 11 |
| Basophils; To High | 0 | 2 |
| Eosinophils; To Low | 0 | 0 |
| Eosinophils; To Normal or No Change | 14 | 13 |
| Eosinophils; To High | 0 | 0 |
| MCH; To Low | 0 | 0 |
| MCH; To Normal or No Change | 14 | 13 |
| MCH; To High | 0 | 0 |
| MCV; To Low | 0 | 0 |
| MCV; To Normal or No Change | 13 | 13 |
| MCV; To High | 1 | 0 |
| Erythrocytes; To Low | 0 | 2 |
| Erythrocytes; To Normal or No Change | 14 | 11 |
| Erythrocytes; To High | 0 | 0 |
| Hematocrit; To Low | 0 | 1 |
| Hematocrit; To Normal or No Change | 13 | 12 |
| Hematocrit; To High | 1 | 0 |
| Hemoglobin; To Low | 0 | 0 |
| Hemoglobin; To Normal or No Change | 14 | 13 |
| Hemoglobin; To High | 0 | 0 |
| Leukocytes; To Low | 0 | 0 |
| Leukocytes; To Normal or No Change | 13 | 13 |
| Leukocytes; To High | 1 | 0 |
| Lymphocytes; To Low | 0 | 0 |
| Lymphocytes; To Normal or No Change | 14 | 12 |
| Lymphocytes; To High | 0 | 1 |
| Monocytes; To Low | 0 | 0 |
| Monocytes; To Normal or No Change | 13 | 13 |
| Monocytes; To High | 1 | 0 |
| Neutrophils; To Low | 0 | 1 |
| Neutrophils; To Normal or No Change | 13 | 12 |
| Neutrophils; To High | 1 | 0 |
| Platelets; To Low | 0 | 0 |
| Platelets; To Normal or No Change | 14 | 13 |
| Platelets; To High | 0 | 0 |
Blood samples were collected at indicated time points for analysis of clinical chemistry parameters including ALT, Albumin, Alk Phos, AST, Bilirubin, Calcium, Carbon Dioxide, Chloride, Creatine Kinase, Creatinine, Direct Bilirubin, Glucose, Magnesium, Potassium, Protein, Sodium, BUN. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| ALT; To Low | 0 | 0 |
| ALT; To Normal or No Change | 14 | 11 |
| ALT; To High | 0 | 2 |
| Albumin; To Low | 0 | 1 |
| Albumin; To Normal or No Change | 14 | 12 |
| Albumin; To High | 0 | 0 |
| Alk Phos; To Low | 0 | 0 |
| Alk Phos; To Normal or No Change | 14 | 13 |
| Alk Phos; To High | 0 | 0 |
| AST; To Low | 0 | 0 |
| AST; To Normal or No Change | 14 | 12 |
| AST; To High | 0 | 1 |
| Bilirubin; To Low | 0 | 1 |
| Bilirubin; To Normal or No Change | 14 | 12 |
| Bilirubin; To High | 0 | 0 |
| Calcium; To Low | 0 | 0 |
| Calcium; To Normal or No Change | 14 | 13 |
| Calcium; To High | 0 | 0 |
| Carbon Dioxide; To Low | 1 | 0 |
| Carbon Dioxide; To Normal or No Change | 13 | 13 |
| Carbon Dioxide; To High | 0 | 0 |
| Chloride; To Low | 0 | 0 |
| Chloride; To Normal or No Change | 14 | 12 |
| Chloride; To High | 0 | 1 |
| Creatine Kinase; To Low | 1 | 0 |
| Creatine Kinase; To Normal or No Change | 13 | 13 |
| Creatine Kinase; To High | 0 | 0 |
| Creatinine; To Low | 0 | 0 |
| Creatinine; To Normal or No Change | 14 | 10 |
| Creatinine; To High | 0 | 3 |
| Direct Bilirubin; To Low | 0 | 0 |
| Direct Bilirubin; To Normal or No Change | 14 | 13 |
| Direct Bilirubin; To High | 0 | 0 |
| Glucose; To Low | 0 | 0 |
| Glucose; To Normal or No Change | 14 | 13 |
| Glucose; To High | 0 | 0 |
| Magnesium; To Low | 0 | 0 |
| Magnesium; To Normal or No Change | 14 | 13 |
| Magnesium; To High | 0 | 0 |
| Potassium; To Low | 0 | 0 |
| Potassium; To Normal or No Change | 14 | 12 |
| Potassium; To High | 0 | 1 |
| Protein; To Low | 0 | 0 |
| Protein; To Normal or No Change | 14 | 13 |
| Protein; To High | 0 | 0 |
| Sodium; To Low | 0 | 0 |
| Sodium; To Normal or No Change | 14 | 13 |
| Sodium; To High | 0 | 0 |
| BUN; To Low | 0 | 0 |
| BUN; To Normal or No Change | 14 | 13 |
| BUN; To High | 0 | 0 |
Urine samples were collected at indicated time points for the analysis of urinalysis parameters including pH of urine, presence of glucose, protein, blood, ketones, bilirubin, nitrite, leukocyte esterase in urine by dipstick. Specific gravity of urine was measured by microscopic examination. Participants were counted in the worst case category that their value changes to (low, normal, high, or abnormal), unless there is no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| Bilirubin; To Normal or No Change | 14 | 13 |
| Bilirubin; To Abnormal | 0 | 0 |
| Glucose; To Normal or No Change | 14 | 13 |
| Glucose; To Abnormal | 0 | 0 |
| Ketones; To Normal or No Change | 14 | 13 |
| Ketones; To Abnormal | 0 | 0 |
| Leukocyte Esterase; To Normal or No Change | 12 | 13 |
| Leukocyte Esterase; To Abnormal | 2 | 0 |
| Nitrite; To Normal or No Change | 14 | 13 |
| Nitrite; To Abnormal | 0 | 0 |
| Occult Blood; To Normal or No Change | 13 | 11 |
| Occult Blood; To Abnormal | 1 | 2 |
| Protein; To Normal or No Change | 14 | 13 |
| Protein; To Abnormal | 0 | 0 |
| pH; To Low | 0 | 0 |
| pH; To Normal or No Change | 14 | 13 |
| pH; To High | 0 | 0 |
| Specific Gravity; To Low | 0 | 0 |
| Specific Gravity; To Normal or No Change | 13 | 13 |
| Specific Gravity; To High | 1 | 0 |
Vital signs including SBP, DBP and pulse rate were measured in a semi-supine position after 5 minutes rest. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| DBP; To Low | 0 | 0 |
| DBP; To Normal or No Change | 14 | 13 |
| DBP; To High | 0 | 0 |
| SBP; To Low | 0 | 0 |
| SBP; To Normal or No Change | 14 | 13 |
| SBP; To High | 0 | 0 |
| Pulse rate; To Low | 0 | 0 |
| Pulse rate; To Normal or No Change | 14 | 13 |
| Pulse rate; To High | 0 | 0 |
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes using an ECG machine that automatically calculated the QTc interval. Number of participants with any increase of \>450 milliseconds in corrected QT interval using the QTcB Interval and QTcF Interval has been reported.
| Participants | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg |
|---|---|---|
| QTcB Interval | 3 | 4 |
| QTcF Interval | 0 | 1 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: AUC(0-24) of Gepotidacin in Plasma | 17.9 ± 28.6 | 8.9 ± 29.6 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: AUC(0-48) of Gepotidacin in Plasma | 19.0 ± 27.7 | 9.5 ± 28.5 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: T1/2 of Gepotidacin in Plasma | 10.882 ± 25.5 | 10.972 ± 17.2 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Liters | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: Vz/F of Gepotidacin in Plasma | 1217.45 ± 37.0 | 2460.46 ± 39.2 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Liters per Hour | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: CL/F of Gepotidacin in Plasma | 77.55 ± 27.6 | 155.43 ± 27.9 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Milligrams | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: Ae Total of Gepotidacin in Urine | 312.73 (286.95 to 340.82) | 156.05 (141.81 to 171.72) |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Hours*micrograms per milliliter | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: AUC(0-24) of Gepotidacin in Urine | 3081.3 (2327.4 to 4079.5) | 1352.4 (1014.2 to 1803.4) |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Hours*micrograms per milliliter | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: AUC(0-48) of Gepotidacin in Urine | 3370.1 (2571.4 to 4417.0) | 1476.8 (1119.2 to 1948.6) |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Liters per Hour | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: CLr of Gepotidacin | 16.49 (15.02 to 18.09) | 17.07 (15.47 to 18.84) |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
| Milligrams | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Ae (0-2) | 12.67 ± 567.5 | NA ± NA |
| Ae (2-4) | 79.84 ± 65.6 | 55.81 ± 47.4 |
| Ae (4-6) | 67.48 ± 44.3 | 21.66 ± 66.4 |
| Ae (6-8) | 33.92 ± 50.5 | 13.82 ± 56.1 |
| Ae (8-12) | 27.59 ± 63.1 | 9.19 ± 50.7 |
| Ae (12-24) | 21.17 ± 79.2 | 11.51 ± 36.4 |
| Ae (24-36) | 11.04 ± 77.9 | 4.74 ± 42.7 |
| Ae (36-48) | 3.61 ± 90.3 | 2.75 ± 31.8 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. fe% was calculated as: (Ae total divided by Dose) multiplied by 100 %.
| Percent dose excreted | Cohort 2:Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Cohort 2: Percentage of the Given Dose of Drug Excreted in Urine (fe%) of Gepotidacin | 20.85 ± 16.9 | 10.42 ± 25.4 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situations as per Medical or scientific judgment.
| Participants | Cohort 2: Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2 (Days 1 to 7) Rifampicin 600 mg | Cohort 2: Period 2 (Days 8 to 9) Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|---|
| Any SAE | 0 | 0 | 0 |
| Any non-SAE | 3 | 2 | 2 |
Blood samples were collected at indicated time points for analysis of hematology parameters including Basophils, Eosinophils, MCH, MCV, Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 2: Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Basophils; To Low | 0 | 0 |
| Basophils; To Normal or No Change | 17 | 16 |
| Basophils; To High | 0 | 1 |
| Eosinophils; To Low | 0 | 0 |
| Eosinophils; To Normal or No Change | 15 | 14 |
| Eosinophils; To High | 2 | 3 |
| MCH; To Low | 0 | 0 |
| MCH; To Normal or No Change | 17 | 17 |
| MCH; To High | 0 | 0 |
| MCV; To Low | 0 | 0 |
| MCV; To Normal or No Change | 17 | 17 |
| MCV; To High | 0 | 0 |
| Erythrocytes; To Low | 0 | 0 |
| Erythrocytes; To Normal or No Change | 17 | 17 |
| Erythrocytes; To High | 0 | 0 |
| Hematocrit; To Low | 0 | 0 |
| Hematocrit; To Normal or No Change | 14 | 15 |
| Hematocrit; To High | 3 | 2 |
| Hemoglobin; To Low | 0 | 0 |
| Hemoglobin; To Normal or No Change | 17 | 17 |
| Hemoglobin; To High | 0 | 0 |
| Leukocytes; To Low | 0 | 1 |
| Leukocytes; To Normal or No Change | 17 | 16 |
| Leukocytes; To High | 0 | 0 |
| Lymphocytes; To Low | 0 | 0 |
| Lymphocytes; To Normal or No Change | 17 | 15 |
| Lymphocytes; To High | 0 | 2 |
| Monocytes; To Low | 1 | 3 |
| Monocytes; To Normal or No Change | 15 | 14 |
| Monocytes; To High | 1 | 0 |
| Neutrophils; To Low | 0 | 4 |
| Neutrophils; To Normal or No Change | 17 | 13 |
| Neutrophils; To High | 0 | 0 |
| Platelets; To Low | 0 | 0 |
| Platelets; To Normal or No Change | 17 | 16 |
| Platelets; To High | 0 | 1 |
Blood samples were collected at indicated time points for analysis of clinical chemistry parameters including ALT, Albumin, Alk Phos, AST, Bilirubin, Calcium, Carbon Dioxide, Chloride, Creatine Kinase, Creatinine, Direct Bilirubin, Glucose, Magnesium, Potassium, Protein, Sodium, BUN. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 2: Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| ALT; To Low | 0 | 0 |
| ALT; To Normal or No Change | 17 | 15 |
| ALT; To High | 0 | 2 |
| Albumin; To Low | 0 | 0 |
| Albumin; To Normal or No Change | 17 | 17 |
| Albumin; To High | 0 | 0 |
| Alk Phos; To Low | 0 | 0 |
| Alk Phos; To Normal or No Change | 17 | 17 |
| Alk Phos; To High | 0 | 0 |
| AST; To Low | 0 | 0 |
| AST; To Normal or No Change | 17 | 16 |
| AST; To High | 0 | 1 |
| Bilirubin; To Low | 0 | 2 |
| Bilirubin; To Normal or No Change | 17 | 15 |
| Bilirubin; To High | 0 | 0 |
| Calcium; To Low | 0 | 0 |
| Calcium; To Normal or No Change | 17 | 17 |
| Calcium; To High | 0 | 0 |
| Carbon Dioxide; To Low | 0 | 3 |
| Carbon Dioxide; To Normal or No Change | 17 | 14 |
| Carbon Dioxide; To High | 0 | 0 |
| Chloride; To Low | 0 | 0 |
| Chloride; To Normal or No Change | 17 | 17 |
| Chloride; To High | 0 | 0 |
| Creatine Kinase; To Low | 0 | 0 |
| Creatine Kinase; To Normal or No Change | 17 | 17 |
| Creatine Kinase; To High | 0 | 0 |
| Creatinine; To Low | 0 | 0 |
| Creatinine; To Normal or No Change | 16 | 16 |
| Creatinine; To High | 1 | 1 |
| Direct Bilirubin; To Low | 0 | 0 |
| Direct Bilirubin; To Normal or No Change | 17 | 17 |
| Direct Bilirubin; To High | 0 | 0 |
| Glucose; To Low | 0 | 0 |
| Glucose; To Normal or No Change | 17 | 16 |
| Glucose; To High | 0 | 1 |
| Magnesium; To Low | 0 | 0 |
| Magnesium; To Normal or No Change | 17 | 17 |
| Magnesium; To High | 0 | 0 |
| Potassium; To Low | 0 | 0 |
| Potassium; To Normal or No Change | 16 | 15 |
| Potassium; To High | 1 | 2 |
| Protein; To Low | 0 | 0 |
| Protein; To Normal or No Change | 17 | 17 |
| Protein; To High | 0 | 0 |
| Sodium; To Low | 0 | 0 |
| Sodium; To Normal or No Change | 17 | 17 |
| Sodium; To High | 0 | 0 |
| BUN; To Low | 0 | 0 |
| BUN; To Normal or No Change | 17 | 17 |
| BUN; To High | 0 | 0 |
Urine samples were collected at indicated time points for the analysis of urinalysis parameters including pH of urine, presence of glucose, protein, blood, ketones, bilirubin, nitrite, leukocyte esterase in urine by dipstick. Specific gravity of urine was measured by microscopic examination. Participants were counted in the worst case category that their value changes to (low, normal, high, or abnormal), unless there is no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 2: Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| Bilirubin; To Normal or No Change | 17 | 16 |
| Bilirubin; To Abnormal | 0 | 0 |
| Glucose; To Normal or No Change | 17 | 16 |
| Glucose; To Abnormal | 0 | 0 |
| Ketones; To Normal or No Change | 17 | 16 |
| Ketones; To Abnormal | 0 | 0 |
| Leukocyte Esterase; To Normal or No Change | 16 | 14 |
| Leukocyte Esterase; To Abnormal | 1 | 2 |
| Nitrite; To Normal or No Change | 17 | 15 |
| Nitrite; To Abnormal | 0 | 1 |
| Occult Blood; To Normal or No Change | 17 | 14 |
| Occult Blood; To Abnormal | 0 | 2 |
| Protein; To Normal or No Change | 17 | 16 |
| Protein; To Abnormal | 0 | 0 |
| pH; To Low | 0 | 0 |
| pH; To Normal or No Change | 17 | 16 |
| pH; To High | 0 | 0 |
| Specific Gravity; To Low | 0 | 0 |
| Specific Gravity; To Normal or No Change | 14 | 15 |
| Specific Gravity; To High | 3 | 1 |
Vital signs including SBP, DBP and pulse rate were measured in a semi-supine position after 5 minutes rest. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 2: Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| DBP; To Low | 0 | 0 |
| DBP; To Normal or No Change | 16 | 14 |
| DBP; To High | 1 | 0 |
| SBP; To Low | 0 | 0 |
| SBP; To Normal or No Change | 17 | 14 |
| SBP; To High | 0 | 0 |
| Pulse rate; To Low | 0 | 0 |
| Pulse rate; To Normal or No Change | 17 | 14 |
| Pulse rate; To High | 0 | 0 |
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes using an ECG machine that automatically calculated the QTc interval. Number of participants with any increase of \>450 milliseconds in corrected QT interval using the QTcB Interval and QTcF Interval has been reported.
| Participants | Cohort 2: Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2: Gepotidacin 1500 mg + Rifampicin 600 mg |
|---|---|---|
| QTcB Interval | 2 | 2 |
| QTcF Interval | 0 | 1 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Micrograms per milliliter | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: Cmax of Gepotidacin in Plasma After the First Dose of 3000 mg (First Dose) | 7.867 ± 36.8 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: Tmax of Gepotidacin in Plasma After the First Dose of 3000 mg (First Dose) | 2.500 (1.00 to 4.07) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: Tlag of Gepotidacin in Plasma After the First Dose of 3000 mg (First Dose) | 0.250 (0 to 1.00) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: AUC(0-tau) of Gepotidacin in Plasma First Dose of 3000 mg (First Dose) | 29.8 ± 30.8 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Micrograms per milliliter | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: Cmax of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose) | 10.051 ± 47.7 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: Tmax of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose) | 2.000 (1.00 to 6.00) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours* micrograms per milliliter | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: AUC(0-tau) of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose) | 41.9 ± 30.2 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Accumulation ratio was calculated as Cmax after the second dose divided by Cmax after the first dose.
| Ratio | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: RoCmax of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose) | 1.278 ± 54.4 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Accumulation ratio was calculated as AUC(0-tau) after the second dose, where 0 is the timepoint prior to second dose, divided by AUC(0-tau) after the first dose, where 0 is the predose timepoint prior to the first dose.
| Ratio | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: RoAUC of Gepotidacin in Plasma After the Second Dose of 3000 mg (Second Dose) | 1.406 ± 27.5 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: AUC(0-24) of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose) | 73.2 ± 26.8 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: AUC(0-48) of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose) | 81.2 ± 25.9 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: AUC(0-t) of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose) | 85.2 ± 20.1 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Liters | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: Vz/F of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose) | 959.42 ± 30.0 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Liters per Hour | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: CL/F of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose) | 69.99 ± 20.1 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: T1/2 of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose+ Second Dose) | 9.501 ± 22.5 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Picograms per milliliter | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: Minimum Observed Concentration (Cmin) of Digoxin in Plasma | 44.127 (34.943 to 55.723) | 77.447 (60.937 to 98.430) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Hours | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: T1/2 of Digoxin in Plasma | 39.367 (37.263 to 41.589) | 32.777 (30.975 to 34.683) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Liters | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: Vz/F of Digoxin in Plasma | 923.75 (810.79 to 1052.46) | 688.49 (602.73 to 786.46) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of digoxin was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Liters per Hour | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: CL/F of Digoxin in Plasma | 16.26 (14.51 to 18.23) | 14.51 (12.91 to 16.31) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Nanograms per milliliter | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: Cmin of Midazolam in Plasma | 0.192 (0.157 to 0.234) | 0.222 (0.181 to 0.273) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Hours | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: T1/2 of Midazolam in Plasma | 5.320 (4.702 to 6.018) | 6.075 (5.358 to 6.887) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Liters | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: Vz/F of Midazolam in Plasma | 615.36 (537.88 to 704.01) | 371.24 (323.51 to 426.01) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of midazolam was conducted using standard non-compartmental analysis. Analysis was performed using a linear mixed-effect model with treatment as a fixed effect and participant as a random effect. Geometric LS mean and 90 % CI of the geometric LS means have been presented.
| Liters per Hour | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Cohort 3: CL/F of Midazolam in Plasma | 80.17 (67.66 to 94.99) | 42.16 (35.47 to 50.10) |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals.
| Milligrams | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: Ae Total of Gepotidacin in Urine Following Two 3000 mg Doses (First Dose + Second Dose ) | 1066.21 ± 40.4 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
| Milligrams | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Ae (0-2), n=17 | NA ± NA |
| Ae (2-4), n=18 | 117.61 ± 101.7 |
| Ae (4-6), n=16 | 103.11 ± 57.3 |
| Ae (6-8); n=16 | 70.98 ± 53.7 |
| Ae (8-12), n=18 | 67.42 ± 44.3 |
| Ae (12-14), n=17 | 64.49 ± 94.1 |
| Ae (14-16), n=15 | 142.36 ± 142.3 |
| Ae (16-18), n=14 | 146.89 ± 59.4 |
| Ae (18-20), n=15 | 93.05 ± 83.5 |
| Ae (20-24), n=17 | 74.44 ± 93.9 |
| Ae (24-36), n=18 | 70.01 ± 105.0 |
| Ae (36-48); n=18 | 20.16 ± 46.4 |
| Ae (48-60), n=18 | 8.51 ± 42.7 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: AUC(0-tau) of Gepotidacin in Urine Following Two 3000 mg Doses (First Dose + Second Dose) | 4770.8 ± 55.2 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: AUC(0-24) of Gepotidacin in Urine Following Two 3000 mg Doses (First Dose + Second Dose) | 14333.9 ± 59.2 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: AUC (0-48) of Gepotidacin in Urine Following Two 3000 mg Doses (First Dose + Second Dose) | 16682.1 ± 59.4 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. fe% was calculated as: (Ae total divided by Dose) multiplied by 100 %.
| Percent dose excreted | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: Percentage of the Given Dose of Drug Excreted in Urine (fe%) Following Two 3000 mg Doses of Gepotidacin (First Dose + Second Dose ) | 17.77 ± 40.4 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Liters per Hour | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|
| Cohort 3: CLr of Gepotidacin Following Two 3000 mg Doses (First Dose + Second Dose) | 13.19 ± 34.6 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situations as per Medical or scientific judgment.
| Participants | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Any SAE | 0 | 0 |
| Any non-SAE | 1 | 11 |
Blood samples were collected at indicated time points for analysis of hematology parameters including Basophils, Eosinophils, MCH, MCV, Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Basophils; To Low | 0 | 0 |
| Basophils; To Normal or No Change | 19 | 18 |
| Basophils; To High | 0 | 0 |
| Eosinophils; To Low | 0 | 0 |
| Eosinophils; To Normal or No Change | 19 | 16 |
| Eosinophils; To High | 0 | 2 |
| MCH; To Low | 0 | 0 |
| MCH; To Normal or No Change | 19 | 18 |
| MCH; To High | 0 | 0 |
| MCV; To Low | 0 | 0 |
| MCV; To Normal or No Change | 18 | 18 |
| MCV; To High | 1 | 0 |
| Erythrocytes; To Low | 2 | 1 |
| Erythrocytes; To Normal or No Change | 17 | 17 |
| Erythrocytes; To High | 0 | 0 |
| Hematocrit; To Low | 1 | 2 |
| Hematocrit; To Normal or No Change | 17 | 14 |
| Hematocrit; To High | 1 | 2 |
| Hemoglobin; To Low | 0 | 1 |
| Hemoglobin; To Normal or No Change | 18 | 15 |
| Hemoglobin; To High | 1 | 2 |
| Leukocytes; To Low | 0 | 0 |
| Leukocytes; To Normal or No Change | 19 | 17 |
| Leukocytes; To High | 0 | 1 |
| Lymphocytes; To Low | 0 | 0 |
| Lymphocytes; To Normal or No Change | 19 | 17 |
| Lymphocytes; To High | 0 | 1 |
| Monocytes; To Low | 0 | 1 |
| Monocytes; To Normal or No Change | 18 | 17 |
| Monocytes; To High | 1 | 0 |
| Neutrophils; To Low | 0 | 0 |
| Neutrophils; To Normal or No Change | 19 | 17 |
| Neutrophils; To High | 0 | 1 |
| Platelets; To Low | 0 | 0 |
| Platelets; To Normal or No Change | 19 | 18 |
| Platelets; To High | 0 | 0 |
Blood samples were collected at indicated time points for analysis of clinical chemistry parameters including ALT, Albumin, Alk Phos, AST, Bilirubin, Calcium, Carbon Dioxide, Chloride, Creatine Kinase, Creatinine, Direct Bilirubin, Glucose, Magnesium, Potassium, Protein, Sodium, BUN. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| ALT; To Low | 0 | 0 |
| ALT; To Normal or No Change | 19 | 17 |
| ALT; To High | 0 | 1 |
| Albumin; To Low | 1 | 0 |
| Albumin; To Normal or No Change | 18 | 17 |
| Albumin; To High | 0 | 1 |
| Alk Phos; To Low | 0 | 0 |
| Alk Phos; To Normal or No Change | 19 | 18 |
| Alk Phos; To High | 0 | 0 |
| AST; To Low | 0 | 0 |
| AST; To Normal or No Change | 18 | 18 |
| AST; To High | 1 | 0 |
| Bilirubin; To Low | 0 | 0 |
| Bilirubin; To Normal or No Change | 19 | 18 |
| Bilirubin; To High | 0 | 0 |
| Calcium; To Low | 1 | 1 |
| Calcium; To Normal or No Change | 18 | 17 |
| Calcium; To High | 0 | 0 |
| Carbon Dioxide; To Low | 0 | 0 |
| Carbon Dioxide; To Normal or No Change | 19 | 18 |
| Carbon Dioxide; To High | 0 | 0 |
| Chloride; To Low | 0 | 0 |
| Chloride; To Normal or No Change | 19 | 17 |
| Chloride; To High | 0 | 1 |
| Creatine Kinase; To Low | 0 | 0 |
| Creatine Kinase; To Normal or No Change | 18 | 18 |
| Creatine Kinase; To High | 1 | 0 |
| Creatinine; To Low | 0 | 0 |
| Creatinine; To Normal or No Change | 19 | 18 |
| Creatinine; To High | 0 | 0 |
| Direct Bilirubin; To Low | 0 | 0 |
| Direct Bilirubin; To Normal or No Change | 19 | 18 |
| Direct Bilirubin; To High | 0 | 0 |
| Glucose; To Low | 0 | 0 |
| Glucose; To Normal or No Change | 19 | 18 |
| Glucose; To High | 0 | 0 |
| Magnesium; To Low | 0 | 0 |
| Magnesium; To Normal or No Change | 19 | 18 |
| Magnesium; To High | 0 | 0 |
| Potassium; To Low | 0 | 0 |
| Potassium; To Normal or No Change | 18 | 18 |
| Potassium; To High | 1 | 0 |
| Protein; To Low | 0 | 0 |
| Protein; To Normal or No Change | 19 | 18 |
| Protein; To High | 0 | 0 |
| Sodium; To Low | 0 | 0 |
| Sodium; To Normal or No Change | 19 | 18 |
| Sodium; To High | 0 | 0 |
| BUN; To Low | 0 | 1 |
| BUN; To Normal or No Change | 19 | 17 |
| BUN; To High | 0 | 0 |
Urine samples were collected at indicated time points for the analysis of urinalysis parameters including pH of urine, presence of glucose, protein, blood, ketones, bilirubin, nitrite, leukocyte esterase in urine by dipstick. Specific gravity of urine was measured by microscopic examination. Participants were counted in the worst case category that their value changes to (low, normal, high, or abnormal), unless there is no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| Bilirubin; To Normal or No Change | 19 | 18 |
| Bilirubin; To Abnormal | 0 | 0 |
| Glucose; To Normal or No Change | 19 | 18 |
| Glucose; To Abnormal | 0 | 0 |
| Ketones; To Normal or No Change | 16 | 17 |
| Ketones; To Abnormal | 3 | 1 |
| Leukocyte Esterase; To Normal or No Change | 13 | 13 |
| Leukocyte Esterase; To Abnormal | 6 | 5 |
| Nitrite; To Normal or No Change | 19 | 18 |
| Nitrite; To Abnormal | 0 | 0 |
| Occult Blood; To Normal or No Change | 14 | 13 |
| Occult Blood; To Abnormal | 5 | 5 |
| Protein; To Normal or No Change | 16 | 16 |
| Protein; To Abnormal | 3 | 2 |
| pH; To Low | 0 | 0 |
| pH; To Normal or No Change | 19 | 18 |
| pH; To High | 0 | 0 |
| Specific Gravity; To Low | 0 | 0 |
| Specific Gravity; To Normal or No Chan | 16 | 10 |
| Specific Gravity; To High | 3 | 8 |
Vital signs including SBP, DBP and pulse rate were measured in a semi-supine position after 5 minutes rest. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the 'To Normal or No Change' category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| DBP; To Low | 0 | 0 |
| DBP; To Normal or No Change | 19 | 18 |
| DBP; To High | 0 | 0 |
| SBP; To Low | 0 | 0 |
| SBP; To Normal or No Change | 19 | 18 |
| SBP; To High | 0 | 0 |
| Pulse rate; To Low | 0 | 0 |
| Pulse rate; To Normal or No Change | 19 | 18 |
| Pulse rate; To High | 0 | 0 |
A 12-lead ECG was recorded with the participant in a semi-supine position after a rest of at least 10 minutes using an ECG machine that automatically calculated the QTc interval. Number of participants with any increase of \>450 milliseconds in corrected QT interval using the QTcB Interval and QTcF Interval has been reported.
| Participants | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg |
|---|---|---|
| QTcB Interval | 2 | 5 |
| QTcF Interval | 0 | 0 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted |
|---|---|---|
| Cohort 4: T1/2 of Gepotidacin Following Single Dose of 1500 mg in Plasma | 12.848 ± 28.5 | 12.540 ± 14.2 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Liters | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted |
|---|---|---|
| Cohort 4: Vz/F of Gepotidacin Following Single Dose of 1500 mg in Plasma | 1246.70 ± 38.8 | 1329.83 ± 17.7 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Liters per Hour | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted |
|---|---|---|
| Cohort 4: CL/F of Gepotidacin Following Single Dose of 1500 mg in Plasma | 67.26 ± 15.5 | 73.50 ± 13.3 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: Tlag of Gepotidacin in Plasma After the First Dose of 3000 mg (First Dose)-Fed State | 0 (0 to 0) |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Liters | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: Vz/F of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)-Fed State | 1251.05 ± 34.5 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Liters per Hour | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: CL/F of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose)-Fed State | 68.83 ± 13.9 |
Blood samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: T1/2 of Gepotidacin in Plasma Following Two 3000 mg Doses (First Dose + Second Dose )-Fed State | 12.599 ± 36.6 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals.
| Milligrams | Cohort 4: Gepotidacin 1500 mg Fed |
|---|---|
| Cohort 4: Ae Total of Gepotidacin Following Single Dose of 1500 mg Under Fed Condition in Urine | 293.50 ± 29.0 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
| Milligrams | Cohort 4: Gepotidacin 1500 mg Fed |
|---|---|
| Ae (0-2) | NA ± NA |
| Ae (2-4) | 102.23 ± 25.2 |
| Ae (4-6) | 60.05 ± 57.0 |
| Ae (6-8) | 31.61 ± 48.9 |
| Ae (8-12) | 16.51 ± 97.0 |
| Ae (12-24) | 17.16 ± 49.3 |
| Ae (24-36) | 5.72 ± 196.5 |
| Ae (36-48) | 4.28 ± 63.2 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 1500 mg Fed |
|---|---|
| Cohort 4: AUC(0-24) of Gepotidacin Following Single Dose of 1500 mg Under Fed Condition in Urine | 2142.4 ± 53.5 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 1500 mg Fed |
|---|---|
| Cohort 4: AUC(0-48) of Gepotidacin Following Single Dose of 1500 mg Under Fed Condition in Urine | 2293.7 ± 53.2 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. fe% was calculated as: (Ae total divided by Dose) multiplied by 100%.
| Percent dose excreted | Cohort 4: Gepotidacin 1500 mg Fed |
|---|---|
| Cohort 4: Percentage of the Given Dose of Drug Excreted in Urine (fe%) for Gepotidacin 1500 mg Under Fed Condition | 19.57 ± 29.0 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Liters per Hour | Cohort 4: Gepotidacin 1500 mg Fed |
|---|---|
| Cohort 4: CLr of Gepotidacin Following Single Dose of 1500 mg Under Fed Condition | 13.42 ± 31.9 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae total was calculated by adding all the fractions of drug collected over all the allotted time intervals.
| Milligrams | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: Ae Total of Gepotidacin in Urine Following Two 3000 mg Doses-Fed State | 1334.42 ± 25.4 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. Ae(t1-t2) measured the amount of drug excreted in urine at defined time intervals.
| Milligrams | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Ae (0-2); n=11 | NA ± NA |
| Ae (2-4); n=10 | 221.19 ± 56.7 |
| Ae (4-6); n=11 | 103.68 ± 70.6 |
| Ae (6-8); n=11 | 67.58 ± 49.5 |
| Ae (8-12); n=11 | 65.06 ± 22.7 |
| Ae (12-14); n=11 | 112.83 ± 66.3 |
| Ae (14-16); n=11 | 174.62 ± 85.2 |
| Ae (16-18); n=11 | 136.66 ± 68.1 |
| Ae (18-20); n=11 | 90.81 ± 25.4 |
| Ae (20-24); n=11 | 80.54 ± 20.4 |
| Ae (24-36); n=11 | 57.62 ± 42.9 |
| Ae (36-48); n=11 | 14.47 ± 36.9 |
| Ae (48-60); n=10 | 9.67 ± 61.7 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: AUC(0-tau) of Gepotidacin in Urine Following Two 3000 mg Doses-Fed State | 4996.9 ± 64.4 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: AUC(0-24) of Gepotidacin in Urine Following Two 3000 mg Doses-Fed State | 14729.5 ± 59.3 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: AUC(0-48) of Gepotidacin in Urine Following Two 3000 mg Doses-Fed State | 15768.2 ± 58.8 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis. fe% was calculated as: (Ae total divided by Dose) multiplied by 100 %.
| Percent dose excreted | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: Percentage of the Given Dose of Drug Excreted in Urine (fe%) of Gepotidacin Following Two 3000 mg Doses-Fed State | 22.24 ± 25.4 |
Urine samples were collected at indicated time points. Pharmacokinetic analysis of gepotidacin was conducted using standard non-compartmental analysis.
| Liters per Hour | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|
| Cohort 4: CLr of Gepotidacin Following Two 3000 mg Dose-Fed State | 14.61 ± 19.3 |
Urine samples were collected at indicated time points. AUC(0-tau) can be calculated only for multiple doses and not for single dose as tau refers to the dosing interval. Hence, AUC(0-tau) could not be calculated for Gepotidacin 1500 mg single dose as mentioned in Reporting and Analysis Plan. The results for this outcome measure will never be posted.
| Hours*micrograms per milliliter | Cohort 4: Gepotidacin 1500 mg Fed |
|---|---|
| Cohort 4: AUC(0-tau) of Gepotidacin Following Single Dose of 1500 mg Under Fed Condition in Urine | NA ± NA |
Collected over Serious adverse events (SAE) and non-serious adverse events (non-SAE) were collected up to 17 days during Cohort 1; up to 26 days during Cohort 2; up to 30 days during Cohort 3 and up to 22 days during Cohort 4.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Gepotidacin 1500 mg | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) |
| Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Cohort 2: Period 1: Gepotidacin 1500 mg | 0/17 (0%) | 0/17 (0%) | 3/17 (17.6%) |
| Cohort 2: Period 2 (Days 1 to 7) Rifampicin 600 mg | 0/17 (0%) | 0/17 (0%) | 2/17 (11.8%) |
| Cohort 2: Period 2 (Days 8 to 9) Gepotidacin 1500 mg + Rifampicin 600 mg | 0/14 (0%) | 0/14 (0%) | 2/14 (14.3%) |
| Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | 0/19 (0%) | 0/19 (0%) | 1/19 (5.3%) |
| Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg | 0/18 (0%) | 0/18 (0%) | 11/18 (61.1%) |
| Cohort 4: Placebo | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Cohort 4: Gepotidacin 1500 mg Fed | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| Cohort 4: Gepotidacin 1500 mg Fasted | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| Cohort 4: Gepotidacin 3000 mg Fed | 0/11 (0%) | 0/11 (0%) | 4/11 (36.4%) |
| Event | Cohort 1: Gepotidacin 1500 mg | Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg | Cohort 2: Period 1: Gepotidacin 1500 mg | Cohort 2: Period 2 (Days 1 to 7) Rifampicin 600 mg | Cohort 2: Period 2 (Days 8 to 9) Gepotidacin 1500 mg + Rifampicin 600 mg | Cohort 3: Digoxin 0.5 mg + Midazolam 2 mg | Cohort 3:Gepotidacin 3000 mg + Digoxin 0.5 mg + Midazolam 2 mg | Cohort 4: Placebo | Cohort 4: Gepotidacin 1500 mg Fed | Cohort 4: Gepotidacin 1500 mg Fasted | Cohort 4: Gepotidacin 3000 mg Fed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/14 | 0/13 | 2/17 | 0/17 | 2/14 | 0/19 | 6/18 | 0/3 | 0/11 | 0/11 | 3/11 |
| NauseaGastrointestinal disorders | 0/14 | 0/13 | 1/17 | 2/17 | 0/14 | 0/19 | 4/18 | 0/3 | 1/11 | 2/11 | 2/11 |
| HeadacheNervous system disorders | 0/14 | 0/13 | 2/17 | 1/17 | 0/14 | 0/19 | 0/18 | 0/3 | 0/11 | 0/11 | 0/11 |
| Electrocardiogram T wave abnormalInvestigations | 0/14 | 0/13 | 0/17 | 0/17 | 0/14 | 1/19 | 2/18 | 0/3 | 0/11 | 0/11 | 0/11 |
| Age, Customized(Participants) | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed | Total |
|---|---|---|---|---|---|---|---|---|
| <18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18-64 years | 14 | 17 | 10 | 9 | 6 | 5 | 3 | 64 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 7 | 4 | 3 | 5 | 2 | 2 | 2 | 25 |
| Male | 7 | 13 | 7 | 4 | 4 | 3 | 1 | 39 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Gepotidacin 1500 mg/Cimetidine + Gepotidacin 1500 mg | Cohort 2: Gepotidacin 1500 mg/Gepotidacin 1500 mg + Rifampicin | Cohort 3: Digoxin+Midazolam/Gepotidacin 3000 mg + Digoxin + Midazolam | Cohort 3: Gepotidacin 3000 mg + Digoxin + Midazolam/Digoxin+Midazolam | Cohort 4:Gepotidacin 1500 mg Fed/Gepotidacin 1500 mg Fasted/Gepotidacin 3000 mg Fed | Cohort 4:Gepotidacin 1500 mg Fasted/Gepotidacin 1500 mg Fed/Gepotidacin 3000 mg Fed | Cohort 4: Placebo Fed/ Placebo Fasted/ Placebo Fed | Total |
|---|---|---|---|---|---|---|---|---|
| BLACK OR AFRICAN AMERICAN | 8 | 7 | 6 | 5 | 0 | 0 | 0 | 26 |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| WHITE | 4 | 5 | 4 | 4 | 0 | 0 | 0 | 17 |
| BLACK OR AFRICAN AMERICAN/WHITE | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| ASIAN(A)/BLACK OR AFRICAN AMERICAN | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| JAPANESE HERITAGE(H)/EAST A H/SOUTH EAST A H | 0 | 2 | 0 | 0 | 6 | 5 | 3 | 16 |
| AMERICAN INDIAN OR ALASKA NATIVE/WHITE | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Aug 2020 to primary completion in Dec 2020, 4 months.
Results were first posted in Mar 2022, 1 year 2 months after primary completion.
Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 4 months is below that.
Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gepotidacin